Influenza HCT contract signed with Traws Pharma

Summary by AI BETAClose X

hVIVO plc has secured a new contract with Traws Pharma to conduct a Phase 2a human challenge trial for Traws' investigational antiviral candidate, tivoxavir marboxil (TXM). This trial, expected to commence in the first half of 2026, will involve approximately 150 healthy participants and will primarily generate revenue in 2026. The study will evaluate TXM's safety, tolerability, and effectiveness in reducing influenza-induced illness, utilizing hVIVO's specialized facilities and recruitment arm, FluCamp. This agreement highlights hVIVO's role as a full-service clinical development partner, capable of accelerating the delivery of crucial efficacy data for novel therapies.

Disclaimer*

Companies

Hvivo (HVO)
UK 100

Latest directors dealings